Based on the ADC Therapeutics SA stock forecast from 3 analysts, the average analyst target price for ADC Therapeutics SA is USD 8.17 over the next 12 months. ADC Therapeutics SA’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ADC Therapeutics SA is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, ADC Therapeutics SA’s stock price was USD 3.67. ADC Therapeutics SA’s stock price has changed by +6.69% over the past week, +173.88% over the past month and +16.14% over the last year.
No recent analyst target price found for ADC Therapeutics SA
No recent average analyst rating found for ADC Therapeutics SA
Company Overview ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. Read Less
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S....Read More
Frequently Asked Questions About ADC Therapeutics SA (ADCT) Stock
Based on ratings from 3 analysts ADC Therapeutics SA's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on ADCT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ADCT is USD 8.17 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 7.
ADCT stock's Price/Earning ratio is -99,999.99.
Our analysis grades ADCT stock's Price / Earning ratio at A-. This means that ADCT stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Biotechnology sector in the NYE exchange.
Based on this ADCT may be undervalued for its sector.
The last closing price of ADCT's stock was USD 3.67.
The most recent market capitalization for ADCT is USD 0.36B.
Based on targets from 3 analysts, the average taret price for ADCT is projected at USD 8.17 over the next 12 months.
This means that ADCT's stock price may go up by +122.52% over the next 12 months.
We can't find any ETFs which contains ADC Therapeutics SA's stock.
As per our most recent records ADC Therapeutics SA has 263 Employees.
ADC Therapeutics SA's registered address is BiopOle, Epalinges, Switzerland, 1066.
You can get more information about it from ADC Therapeutics SA's website at https://www.adctherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Frequently Asked Questions About ADC Therapeutics SA (ADCT) Stock
Based on ratings from 3 analysts ADC Therapeutics SA's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on ADCT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ADCT is USD 8.17 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 7.
ADCT stock's Price/Earning ratio is -99,999.99.
Our analysis grades ADCT stock's Price / Earning ratio at A-. This means that ADCT stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Biotechnology sector in the NYE exchange.
Based on this ADCT may be undervalued for its sector.
The last closing price of ADCT's stock was USD 3.67.
The most recent market capitalization for ADCT is USD 0.36B.
Based on targets from 3 analysts, the average taret price for ADCT is projected at USD 8.17 over the next 12 months.
This means that ADCT's stock price may go up by +122.52% over the next 12 months.
We can't find any ETFs which contains ADC Therapeutics SA's stock.
As per our most recent records ADC Therapeutics SA has 263 Employees.
ADC Therapeutics SA's registered address is BiopOle, Epalinges, Switzerland, 1066.
You can get more information about it from ADC Therapeutics SA's website at https://www.adctherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ADCT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
